ERBB2 and breast carcinoma: Adjuvant chemotherapy plus trastuzumab (Cost per QALY = 4,756 USD) was not a cost-effective option for treating patients with HER2-positive early breast cancer versus adjuvant chemotherapy alone (Cost per QALY = 1,115 USD) from Iranian health system perspective [17].